A look at two biopharma companies that fall into this category that investors should check out. Source: BioSpace

Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III. Source: BioSpace

Three biotech companies want to start out the new year with a new start. Source: BioSpace

At closing of the agreement, $75 million in aggregate principal amount of the Senior Secured Notes were issued. Source: BioSpace

From around 2014 through 2016, Valeant seemingly had a crisis story per week, ranging from insider trading to channel stuffing Source: BioSpace

In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors. Source: BioSpace

BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2016. Source: BioSpace

Menlo Therapeutics filed on Thursday with the SEC to raise up to $98M in an IPO. Source: BioSpace

ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace

A look at a few biotechs which should outperform the market in 2018: Source: BioSpace